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Results Following the key opening of the blinding proto-
col, we analyzed 91 eligible patients (tJ-14: 45, placebo: 
46) using a “per protocol set” analysis. the incidence of 
≧grade 2 COM was 40.0 % in the tJ-14 group and 41.3 % 
in the placebo group (p = 0.588). the median duration of 
≧grade 2 COM was 14 days in the tJ-14 group and 16 days 
in the placebo group (p = 0.894). Meanwhile, the median 
duration of any grade of COM was 9 days in the tJ-14 
group and 17 days in the placebo group among the patients 
who developed grade 1 symptoms during the screening 
cycle [hazard ratio 0.60; 95 % CI (0.23–1.59), p = 0.290].
Conclusions although tJ-14 treatment did not reduce 
the incidence of ≥2 COM in the patients who developed 
mucositis during chemotherapy for gastric cancer, a trend 
was observed in which tJ-14 reduced the risk of COM in the 
patients who developed grade 1 COM during the screening 
cycle. Further, phase III studies with a larger sample size are 
needed to clarify the protective effects of tJ-14 for COM.
Abstract 
Background Hangeshashinto (tJ-14, a Kampo medicine), 
which reduces the level of prostaglandin e2 and affects the 
cyclooxygenase activity, alleviates chemotherapy-induced 
oral mucositis (COM). We conducted a randomized com-
parative trial to investigate whether tJ-14 prevents and 
controls COM in patients with gastric cancer.
Methods We randomly assigned patients with gastric 
cancer who developed moderate-to-severe oral mucositis 
(CtCae v4.0 grade ≧1) during any cycle of chemotherapy 
to receive either tJ-14 or a placebo as a double-blind trial. 
the patients received a placebo or tJ-14 for 2–6 weeks 
according to the chemotherapy regimen from the beginning 
of the next course of chemotherapy. the primary end point 
was the incidence of grade ≧2 oral mucositis in the proto-
col treatment course, and the secondary end points were the 
time to disappearance of oral mucositis and the incidence 
of adverse events.
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Introduction
gastric cancer is the second most frequent cancer-related 
cause of death after lung cancer [1]. Chemotherapy is one 
of the most important modalities for treating advanced 
gastric cancer as well as curatively resected cancers in 
the adjuvant setting. numerous chemotherapy regimens 
have been used in cases of operable or inoperable gas-
tric cancer [2–5]. although several studies have shown 
that chemotherapy improves and prolongs survival, it 
often causes severe toxicity, seriously compromising the 
patient’s quality of life and precluding the continuation of 
the treatment.
Oral mucositis is a common toxicity associated with 
cytotoxic chemotherapy used in the gastric cancer treat-
ment. In pivotal phase III trials of chemotherapy for gas-
tric cancer, the incidence of all grades of chemother-
apy-induced oral mucositis (COM) was observed to be 
6.3–32 % [4–8]. COM results in severe discomfort, impair-
ing the patient’s ability to eat, swallow, and talk, and has 
an indirect effect on tumor outcomes, as its presence often 
necessitates the unfavorable modification of anticancer 
therapy, such as breaks in the administration of chemother-
apy or dose reduction in the chemotherapy regimen [9–11]. 
One factor associated with COM exacerbation is the activa-
tion of the cyclooxygenase pathway, which mediates ulcer 
formation and pain via the upregulation of pro-inflamma-
tory prostaglandins. Indeed, richard et al. demonstrated, 
after having enlisted 20 patients treated with chemotherapy 
drugs and performing a biopsy of the oral mucosa in each 
case, a statistically significant increase in the number of 
endothelial cells in the oral mucosa with nuclear factor-
kappa B (nF-κB) and cyclooxygenase 2 (COX-2) expres-
sions in the postchemotherapy treatment period compared 
to that observed in the pretreatment period. the expres-
sion of COX-2 in these cells represents the initial sign of 
the inflammatory cascade that determines the production 
of prostaglandins and further tissue damage. COX-2 is also 
upregulated by nF-κB, which plays an important role in 
the inflammatory process [12]. COM invariably requires 
treatment with systemic analgesics, adjunctive medica-
tions, physical therapy, and psychological therapy in addi-
tion to oral care [13]. treatment guidelines developed by 
the Multinational association of Supportive Care in Can-
cer and the International Society for Oral Oncology have 
been published; however, they also highlighted the need for 
a higher level of evidence [14]. although a range of inter-
ventions have been developed to prevent and treat COM, a 
more rational approach is warranted [11].
Hangeshashinto (tJ-14) is a traditional Japanese medi-
cine containing 7 herbal crude drugs. Seven herbal crude 
drugs are as follows; Pinelliae tuber, Scutellariae radix, 
glycyrrhizae radix, Zizyphi Fructus, ginseng radix, Zin-
giberis Processum rhizoma, and Coptidis rhizome [15–17]. 
tJ-14 is prescribed in Japan to treat inflammatory diarrhea, 
gastritis, and stomatitis. recently, Kono et al. [18] found 
that tJ-14 was effective as a gargle therapy for the treat-
ment of COM in a pilot clinical study and a randomized, 
placebo-controlled clinical trial. tJ-14 has been demon-
strated to directly inhibit Pge2 production in human gingi-
val fibroblasts and reduce the Pge2 content in the colon in 
several animal models of diarrhea using anticancer drugs, 
cholera toxin, or castor oil, resulting in the amelioration of 
inflammatory damage [19–22]. It has also been reported 
that some ingredients of tJ-14 inhibit Pge2 production 
and/or the COX-2 expression [23–32]. Phenylpropanoids, 
such as [6]-shogaol and [6]-gingerol, flavonoids, such as 
wogonin, baicalein, and baicalin, and isoquinoline alka-
loids, such as berberine, are well established to possess an 
anti-Pge2 activity via various particular mechanisms.
Considering these clinical and biochemical study find-
ings, in the present study, the efficacy of tJ-14 in the pre-
vention and/or treatment of COM was investigated in a ran-
domized, double-blind, placebo-controlled clinical trial of 
patients receiving chemotherapy for gastric cancer.
Materials and methods
Study design
a prospective, multi-institutional, randomized, double-
blind, placebo-controlled phase II trial was performed 
in patients receiving chemotherapy for gastric cancer in 
Japan. Patients who developed CtCae v4.0 ≧grade 1 oral 
mucositis during the screening cycle of chemotherapy were 
considered eligible for inclusion in this study. the eligible 
patients were centrally randomized to receive either tJ-14 
or a placebo during their next cycle of chemotherapy. the 
patients were stratified according to age, chemotherapy reg-
imen, institution, and previous treatment for oral mucositis 
before randomization in a 1:1 ratio. a specially made and 
prepared matched placebo was utilized to confirm blinding.
the primary objective of this study was to determine the 
efficacy and safety of tJ-14 compared with the placebo. 
the primary end point was the incidence of ≥grade 2 oral 
mucositis, and the worst oral mucositis grade observed 
throughout the protocol therapy was assessed. as for sever-
ity, the worst grade observed on the day of the medication 
was evaluated instead of the mean circadian change. the 
secondary end points were the time to disappearance of 
oral mucositis and the incidence of adverse events.
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ethics
the study data and informed consent were obtained in 
accordance with the Declaration of Helsinki, and the study 
protocol was approved by the ethics review Board of each 
institution. the institutions where ethics was obtained were 
as follows: Kanagawa Cancer Center, Osaka general Medi-
cal Center, Chiba Cancer Center, Hiroshima University, 
Kinki University, teikyo University, toyonaka Municipal 
Hospital, Hiroshima City asa Hospital, Prefectural aichi 
Hospital, Kochi University, Minoh City Hospital, national 
Hospital Organization nagoya Medical Center, Shizuoka 
general Hospital, nagoya City University, and Osaka-Kita-
teishin Hospital. all patients were given a written expla-
nation of the study protocol and provided their written 
informed consent before participating.
Inclusion and exclusion criteria
Patients 20 years of age or older who were undergoing 
chemotherapy for gastric cancer were considered eligible 
for this study. Patients who developed moderate-to-severe 
oral mucositis (CtCae v4.0 grade ≧1) during any cycle 
of chemotherapy (S-1, paclitaxel, irinotecan, cisplatin, etc.) 
were asked to be enrolled in the study. all participants were 
required to have a “good” performance status (i.e., scores 
of 0 or 1 on the eastern Cooperative Oncology group per-
formance status scale). Patients with any of the follow-
ing characteristics were not eligible for the study: use of 
Kampo medicine within 2 weeks before registration and a 
history of severe hypersensitivity (allergy) to any medicine 
containing antiphlogistics, analgesics, opioids, or steroids. 
Patients with serious constipation and pregnant or lactating 
females were excluded from the study. any other medical 
conditions that made a patient unsuitable for inclusion in 
the study according to the opinion of the investigator were 
also considered to be exclusion criteria for this study.
Chemotherapy
gastric cancer chemotherapy was administered according 
to the protocols of each treatment, and the administration 
of each agent was described in case report form. Patients 
enrolled in this study received the following chemotherapy.
group a: S-1 monotherapy. S-1: the treatment regimen 
consisted of 6-week cycles in which 80 mg/m2 per day 
was given for 4 weeks followed by 2-week rest for adju-
vant setting and 5-week cycles in which 80 mg/m2 per 
day for 3 weeks followed by 2-week rest for advanced 
gastric cancer patients
group B: S-1 plus cisplatin. S-1: 80 mg/m2 oral admin-
istration (p.o.) daily for 21 days, every 5 weeks. Cis-
platin: 60 mg/m2 intravenous drip (d.i.v.) day 8, every 
5 weeks.
group C: S-1 plus paclitaxel. S-1: 80 mg/m2 p.o. daily 
on days 1–14 of 3 weeks cycle. Paclitaxel: 50 mg/m2 
d.i.v. days 1, 8 every 3 weeks.
group D: paclitaxel. Paclitaxel: 80 mg/m2 d.i.v. days 1, 
8, 15, every 4 weeks.
group e: S-1 plus docetaxel. S-1: 80 mg/m2 p.o. daily 
on days 1–14 of 3 weeks cycle. Docetaxel: 40 mg/m2 
d.i.v. days 1 every 3 weeks.
group F: docetaxel. Docetaxel: 60 mg/m2 d.i.v. days 1 
every 3 weeks.
group g: CPt-11 plus cisplatin. CPt-11: 60 mg/m2 
d.i.v. days 1 every 2 weeks. Cisplatin: 30 mg/m2 d.i.v. 
days 1 every 2 weeks.
group H: CPt-11. CPt-11: 150 mg/m2 d.i.v. days 1 
every 2–3 weeks
Study drug
Both tJ-14 and the placebo were administered at a dose of 
2.5 g/three times per day (for a total daily dose of 7.5 g). 
the placebo formulation matched the texture, flavor, and 
other characteristics of the active drug. the patients were 
advised to dissolve 2.5 g of tJ-14 or the placebo in 50 ml 
of drinking water and rinse their oral cavity with the solu-
tion three times daily for 10 s. the test drug was adminis-
tered from the first day to final day of the protocol treat-
ment course. after the protocol treatment course, tJ-14 
was administrated for one course, as much as possible. the 
patients followed the oral care instructions throughout the 
treatment period before the next course of chemotherapy 
began. no other prophylactic mouthwashes or treatments 
for mucositis were allowed in this clinical trial.
Study assessment
the signs and symptoms of oral mucositis were assessed 
by the investigator during the screening cycle. the CtCae 
v4.0 grading (table 1) was used to assess the severity of 
oral mucositis. the time to healing of oral mucositis was 
defined as the period from the start date of the protocol 
treatment or the date of onset of oral mucositis to the date 
when all oral mucositis symptoms disappeared. If all oral 
mucositis symptoms fail to disappear within the study 
treatment period, the observation shall be continued until 
symptom disappearance. additionally, the patients reported 
their own ability to eat solid foods. Safety was assessed 
throughout the study using physical examinations, includ-
ing inspection of the oral tissue, hematology and serum 
chemistry laboratory tests, and adverse event reporting. 
any adverse event, whether related or unrelated to the 
study drug, was reported with the date and time of onset, 
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severity, pattern, action taken, and outcome. If the adverse 
event had not resolved at the time the case report forms 
were collected, a follow-up report was provided a later 
date. If no follow-up report was provided, the investigator 
had to provide justification. all adverse events were fol-
lowed until they either resolved or the investigator deter-
mined that the event was no longer clinically significant.
Statistical analysis
the eligible patients were randomly assigned on a 1:1 
ratio to receive either tJ-14 or the placebo. after check-
ing patient eligibility, randomization was carried out cen-
trally at the data center using dynamic randomization with 
main prognostic factors, including the chemotherapy regi-
men (postoperative adjuvant chemotherapy, unresectable 
metastatic/recurrent lesions), presence/absence of previous 
treatment of oral mucositis, age (≥60 years, <60 years), 
and institution.
assuming an incidence of grade 2 or worse COM of 
10 % in the tJ-14 group and 35 % in the placebo group, a 
sample size of 42 for each group was estimated to have at 
least 80 % power under a significance level of two-sided 
10 %. therefore, in order to account for possible dropouts, 
a target sample size of 90 patients was required.
the difference in the incidence of grade 2 or worse 
COM between the groups and its 90 % confidence inter-
val was calculated. Comparisons were made using the chi-
squared test. the baseline characteristics were compared 
using the chi-squared test for categorical variables and the 
Wilcoxon test for continuous variables. the Kaplan–Meier 
method, log-rank test, and Cox proportional hazard regres-
sion model were used to assess the time to healing among 
the patients with COM. a hazard ratio (Hr) smaller than 1 
indicated that tJ-14 accelerated the healing of COM. the 
frequencies of adverse events were compared using Fish-
er’s exact test. all p values were two-sided. the statistical 
analyses were performed using the SaS software package 
for Windows, release 9.3 (SaS Institute, Cary, nC).
Results
Patients
Of the patients receiving chemotherapy for gastric cancer, 91 
who developed CtCae v4.0 ≧grade 1 oral mucositis dur-
ing the screening cycle and provided informed consent were 
randomized to either the tJ-14 (n = 45) or placebo (n = 46) 
group. the baseline demographics and disease characteristics 
of the per protocol set (PPS) population are shown in table 2. 
a total of 61.5 % of the subjects were male, and 38.5 % of 
the subjects were female; the median age was 68 years (range 
36–89 years). all patients had histologically confirmed gastric 
adenocarcinoma. there were no disparities between the two 
PPS randomized groups. the majority of patients received S-1 
adjuvant (48.4 %) or S-1-based doublet (22.0 %) regimens, 
and the treatment groups were balanced for the chemotherapy 
regimen (table 2). no patients received radiation therapy or 
molecular targeting agents before enrollment. no patients 
were enrolled in the study if there was any clinical evidence of 
another active oral mucosal disease at baseline.
Incidence and duration of COM
the incidence of ≧grade 2 COM was 40 % (18 patients) 
in the tJ-14 group and 41.3 % (19 patients) in the placebo 
group, and there was no significant difference between the 
two groups (p = 0.588); the primary end point was not 
met in this study. More, when comparing the duration of 
≧grade 2 COM between the two treatment groups, there 
was not significantly difference (Hr 0.97 (0.41–2.29) log-
rank p = 0.937) (Fig. 1).
However, among the patients who developed grade 
1 COM during the screening cycle, the median duration 
of any grade of COM was 9.0 days in the tJ-14 group 
and 17.0 days in the placebo group [Hr 0.598; 95 % CI 
(0.226–1.585), p = 0.290] (Fig. 2). treatment with tJ-14 
reduced the duration of any grade of COM compared with 
the placebo.
Chemotherapy treatment failure during the protocol 
treatment
Chemotherapy treatment failure was observed in 26.7 % 
(12 patients) of the subjects in the tJ-14 group and 21.7 % 
(10 patients) of the subjects in the placebo group. For most 
chemotherapy regimens, there were no significant differ-
ences with regard to the incidence of the treatment failure.
Safety
Hematological, blood biochemistry, and non-hematological 
toxicities were analyzed. the most commonly reported 
Table 1  Severity of oral mucositis
Common terminology Criteria for adverse events (CtCae) Version 
4.0
grade 1 asymptomatic or mild symptoms;
Intervention not indicated
grade 2 Moderate pain; not interfering with oral intake;
Modified diet indicated
grade 3 Severe pain;
Interfering with oral intake
grade 4 life-threatening consequence;
Urgent intervention indicated
grade 5 Death
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treatment-related adverse events were anorexia, a change 
in PS, nausea, neutropenia, and diarrhea, all of which typi-
cally occur in cancer patients receiving cytotoxic chemo-
therapy (table 3). the majorities of these events were mild 
to moderate in severity and considered to be unrelated to 
the study drug.
Discussion
to date, this randomized trial is the first evaluation of the 
use of tJ-14 to treat COM in patients with gastric can-
cer in a prospective placebo-controlled randomized phase 
II study. the primary purpose of this study was to prove 
the effects of tJ-14 in reducing the incidence of ≧grade 2 
oral mucositis. the incidence of oral mucositis of ≧grade 2 
was 40.0 % in the tJ-14 group and 41.3 % in the placebo 
group in the overall study population. therefore, treatment 
with tJ-14 did not exhibit any effect with regard to reduc-
ing the frequency of grade 2 events or the duration of grade 
2 chemotherapy-induced oral mucositis in gastric cancer 
patients receiving fluorinated pyrimidine-based chemo-
therapy. Why did this trial not meet its primary objec-
tive? the most likely reason is that the dose reduction of 
chemotherapy performed before the administration of tJ-
14 treatment may have affected the incidence and dura-
tion of COM. generally, among patients who developed 
≧grade 2 COM before being entered into this study, the 
physicians may have been inclined to stop or postpone the 
Table 2  Patient characteristics of the tJ-14 and placebo groups
CDDP Cisplatin, PTX Paclitaxel, DTX Docetaxel, 5-FU 5-fluoroura-
cile
treatment Placebo (N = 46) tJ-14 (N = 45) p value
Sex
Male 28 (60.9 %) 28 (62.2 %) 0.895
Female 18 (39.1 %) 17 (37.8 %)
Age
Median 67.5 68.0 0.648
range 42.0–89.0 36.0–84.0
PS
0 38 (82.6 %) 39 (86.7 %) 0.855
1 5 (10.9 %) 4 (8.9 %)
2 3 (6.5 %) 2 (4.4 %)
Status
adjuvant 21 (45.7 %) 23 (51.1 %) 0.602
advanced 25 (54.3 %) 22 (48.9 %)
Oral care (patients)
+ 3 (6.5 %) 2 (4.4 %) 0.664
− 43 (93.5 %) 43 (95.6 %)
Oral care (institution)
+ 11 (23.9 %) 7 (15.6 %) 0.317
− 35 (76.1 %) 38 (84.4 %)
Chemotherapy at the time of registration
S-1 19 (42.2 %) 25 (55.6 %) 0.490
S-1 + CDDP 3 (6.7 %) 5 (11.1 %)
S-1 + DtX 6 (13.3 %) 1 (2.2 %)
S-1 + PtX 2 (4.4 %) 3 (6.7 %)
DtX 1 (2.2 %) 1 (2.2 %)
PtX 3 (6.7 %) 2 (4.4 %)
CPt-11 + CDDP 1 (2.2 %) 2 (4.4 %)
CPt-11 3 (6.7 %) 1 (2.2 %)
5-FU + CDDP 0 (0 %) 1 (2.2 %)
other 7 (15.6 %) 4 (8.9 %)
Fig. 1  Duration of ≧grade 2 chemotherapy-induced oral mucositis in 
the treatment group
Fig. 2  Duration of any grade of chemotherapy-induced oral mucosi-
tis in the patients who developed grade 1 oral mucositis during the 
screening cycle
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original chemotherapy and reduce the dose at the time of 
the next chemotherapy cycle, which was exactly the time 
of study treatment and observation [33]. the incidence of 
oral mucositis of ≧grade 2 was 36.4 % in the patients who 
received chemotherapy dose reduction and 42.0 % in the 
patients who did not receive dose reduction. With regard to 
the incidence of toxicity in this study, 36 patients developed 
CtCae v4.0 ≧grade 2 oral mucositis during the screening 
cycle. among these patients, seven received dose reduction 
before the protocol cycle. the median duration of ≧grade 
2 oral mucositis was 10.0 days in the patients treated with 
prophylactic dose reduction and 16.0 days in the patients 
treated without prophylactic dose reduction. there was a 
significant difference between the two groups (p = 0.034). 
It has been reported that the COM was depending on the 
dose and type of chemotherapy [34, 35]. Coleman et al. 
[36] evaluated 116 women with measurable metastatic 
breast cancer participated in a randomized phase II study of 
single-agent liposomal pegylated doxorubicin given either 
as a 60 mg/m2 every 6 weeks (arM a) or 50 mg/m2 every 
4 weeks (arM B) schedule. they found that the adverse 
event profiles of the two schedules were distinctly different, 
and mucositis was more common with arM a (35 % CtC 
grade 3/4 in arM a, 14 % in arM B). More, elting et al. 
[37] retrospectively analyzed 599 patients who developed 
chemotherapy-induced oral mucositis. they found that a 
reduction in the dose of the next cycle of chemotherapy 
was twice as common after cycles with mucositis as it was 
after cycles without mucositis (23 vs. 11 %; p ≤ 0.0001). 
taking these findings into consideration, dose reduction 
in the chemotherapy regimen may have been a key issue 
improving the incidence and/or the duration of COM. We 
assume that the effects of tJ-14 in oral mucositis may be 
less prominent due to the use of chemotherapy dose reduc-
tion just before the experimental cycles. taking these find-
ings into consideration, dose reduction in the chemotherapy 
regimen may have been a key issue improving the inci-
dence and duration of COM. We assume that the effects of 
tJ-14 in oral mucositis may be less prominent due to the 
use of chemotherapy dose reduction just before the experi-
mental cycles.
a borderline significant difference, however, was 
observed in the patients who developed ≧grade 1 COM at 
the time of screening. the median duration of any grade 
of oral mucositis was 9.0 days in the tJ-14 group and 
17.0 days in the protocol treatment cycle group. treat-
ment with tJ-14 reduced the duration of any grade of oral 
mucositis compared with the placebo. In patients with 
grade 1 COM before the experimental cycle, it is presumed 
that the physicians may not have reduced the chemotherapy 
Table 3  Hematological and biochemical toxicities observed during the treatment
AST aspartate aminotransferase
≥grade 1 ≥grade 2
tJ-14 (N = 45) Placebo (N = 46) p value tJ-14 (N = 45) Placebo (N = 46) p value
Hematological toxicity
leucopenia 5 (11 %) 8 (17 %) 0.39 0 (0 %) 1 (2 %) 0.32
neutropenia 7 (16 %) 7 (15 %) 0.96 3 (7 %) 4 (9 %) 0.72
Hemoglobin 37 (82 %) 40 (87 %) 0.53 13 (29 %) 8 (17 %) 0.19
Platelet 4 (9 %) 6 (13 %) 0.53 0 (0 %) 1 (2 %) 0.32
t-Bilirubin 3 (7 %) 4 (9 %) 0.72 0 (0 %) 0 (0 %) 1.00
aSt 2 (4 %) 2 (4 %) 0.98 0 (0 %) 0 (0 %) 1.00
Non-hematological toxicity
anorexia 18 (40 %) 19 (41 %) 0.90 8 (18 %) 4 (9 %) 0.20
nausea 7 (16 %) 9 (20 %) 0.62 2 (4 %) 2 (4 %) 0.98
Vomiting 3 (7 %) 2 (4 %) 0.63 0 (0 %) 1 (2 %) 0.32
Diarrhea 5 (11 %) 4 (9 %) 0.70 0 (0 %) 1 (2 %) 0.32
Constipation 3 (7 %) 5 (11 %) 0.48 0 (0 %) 1 (2 %) 0.32
Peripheral neuropathy 1 (2 %) 1 (2 %) 0.99 0 (0 %) 1 (2 %) 0.32
lassitude 3 (7 %) 3 (7 %) 0.99 0 (0 %) 1 (2 %) 0.32
Hand-foot syndrome 0 (0 %) 1 (2 %) 0.32 0 (0 %) 1 (2 %) 0.32
Skin reaction 2 (4 %) 0 (0 %) 0.15 0 (0 %) 1 (2 %) 1.00
Dysgeusia 2 (4 %) 1 (2 %) 0.54 1 (2 %) 1 (2 %) 0.99
edema 1 (2 %) 1 (2 %) 0.99 0 (0 %) 1 (2 %) 0.32
Change in PS 8 (18 %) 9 (20 %) 0.83 2 (4 %) 3 (7 %) 0.66
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dose. therefore, most of the patients who developed 
COM of grade 1 were not influenced by dose reduction 
of chemotherapy. these results suggest that the effects of 
tJ-14 would have been more prominent if chemotherapy 
dose reduction had not been performed before the experi-
mental cycles. as mentioned above, it has been previously 
reported that tJ-14 exerts an anti-inflammatory effect by 
suppressing the levels of lipopolysaccharide-induced Il-6 
and Il-8, and cyclooxygenase (COX)-1 and COX-2 [38, 
39], in a dose-dependent manner [40]. Further studies are 
needed to clarify the exact mechanisms underlying these 
observations.
In conclusion, this trial did not show a beneficial effect 
of tJ-14 in reducing the incidence of chemotherapy-
induced oral mucositis as the primary end point, likely 
due to the use of dose reduction before the experimen-
tal cycles, which was not prohibited by the study pro-
tocol. In the patients with >grade 1 COM at the screen-
ing cycle, an obvious reduction in the risk of COM (Hr 
0.60) was demonstrated. In this regard, the addition of 
tJ-14 to chemotherapy regimens may have shortened the 
duration of oral mucositis when no dose reduction was 
performed before the administration of the experimental 
agents. a further analysis may lead to a better interpreta-
tion of the study results by examining subgroups that will 
benefit from tJ-14 treatment. a more definitive design 
in a future trial of tJ-14 for chemotherapy-induced oral 
mucositis is needed to eliminate the influence of arbitrary 
dose reduction based on the discretion of the individual 
physician.
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